Breast cancer deaths in the US continue to fall, but new report …
Oct 1, 2024 · The study, published Tuesday in CA: A Cancer Journal for Clinicians, found some good news: The overall breast cancer death rate in the US dropped about 44% between 1989 and 2022, which...
Breast Cancer Continues to Rise Among Younger Women, Study …
Oct 1, 2024 · Breast cancer continues to be the leading cause of cancer deaths among Black women, who have a 38 percent higher death rate than white women.
Strongest contender in decades in fight against breast cancer
Feb 12, 2024 · FULL STORY. For decades, hormonal treatment of breast cancer has been going in one direction -- blocking estrogen. Now a global study involving researchers at the University of Adelaide has...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
Sep 17, 2024 · Kisqali® (ribociclib) is a CDK4/6 inhibitor that reduces the risk of recurrence by 25% in people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence. The FDA approval is based on the Phase III NATALEE trial, which showed a consistent benefit across all subgroups, including node-negative disease.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
Oct 19, 2021 · Enhertu (trastuzumab deruxtecan) is a chemotherapy-linked antibody that kills HER2-positive breast cancer cells and nearby cells. A clinical trial showed that it was more effective than T-DM1 at delaying disease progression and shrinking tumors.
Cleveland Clinic Announces Next Step in Preventive Breast Cancer ...
Feb 8, 2023 · Cleveland Clinic researchers have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, the new phase 1b study will enroll cancer-free individuals at high risk for developing breast cancer who have …
Breast cancer metastasis on/off switch revealed - Stanford News
Dec 20, 2023 · A protein called ENPP1 controls breast cancer's ability to resist immunotherapy and metastasize, according to a study by Stanford and Arc Institute. High ENPP1 levels are linked to poor prognosis and low response to pembrolizumab, a common immunotherapy drug.
In Reversal, Expert Panel Recommends Breast Cancer Screening at …
For women with dense breasts who are at average risk of breast cancer, recent research indicates that M.R.I. is the best supplemental scan, Dr. Destounis said, “with far better cancer …
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast ...
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns …
New Treatments Emerge for Metastatic HER2+ Breast Cancer
Jan 8, 2020 · Learn about two new drugs, tucatinib and trastuzumab deruxtecan, that showed promising results in clinical trials for women with previously treated HER2-positive breast cancer that has spread. Find out how they work, who can benefit, and what side effects to watch out for.